Works matching IS 20734468 AND DT 2016 AND VI 5 AND IP 1
Results: 6
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer.
- Published in:
- Antibodies (2073-4468), 2016, v. 5, n. 1, p. 6, doi. 10.3390/antib5010006
- By:
- Publication type:
- Article
Cytokines in the Germinal Center Niche.
- Published in:
- Antibodies (2073-4468), 2016, v. 5, n. 1, p. 5, doi. 10.3390/antib5010005
- By:
- Publication type:
- Article
Acknowledgement to Reviewers of Antibodies in 2015.
- Published in:
- Antibodies (2073-4468), 2016, v. 5, n. 1, p. 4, doi. 10.3390/antib5010004
- Publication type:
- Article
Anticytokine Autoantibodies: Association with Infection and Immune Dysregulation.
- Published in:
- Antibodies (2073-4468), 2016, v. 5, n. 1, p. 3, doi. 10.3390/antib5010003
- By:
- Publication type:
- Article
Autoantibodies in SLE: Specificities, Isotypes and Receptors.
- Published in:
- Antibodies (2073-4468), 2016, v. 5, n. 1, p. 2, doi. 10.3390/antib5010002
- By:
- Publication type:
- Article
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
- Published in:
- Antibodies (2073-4468), 2016, v. 5, n. 1, p. 1, doi. 10.3390/antib5010001
- By:
- Publication type:
- Article